Literature DB >> 19964369

Creatine and phosphate pools are maintained at energetically optimal levels in the heart during hypertrophic remodeling and heart failure.

Daniel A Beard1, Fan Wu.   

Abstract

The ability of mitochondria to oxidatively synthesize ATP from ADP and inorganic phosphate is compromised in the failing heart. Specifically, the magnitude of the free energy at which ATP is synthesized in heart failure is diminished compared to control. However the causal mechanisms involved are not clearly understood. Here we used computer simulation to analyze the impact of reduction in three cytoplasmic metabolic pools that is observed with hypertrophic remodeling and heart failure. Our simulations, which are validated based on in vivo data on phosphate metabolites in both the healthy and diseased heart, predict that, given a prescribed reduction in the total adenine nucleotide pool, the pools of total creatine and total exchangeable phosphate are maintained at levels that maintain the ATP hydrolysis potential of the heart at near the normal physiological value.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19964369      PMCID: PMC2805853          DOI: 10.1109/IEMBS.2009.5333680

Source DB:  PubMed          Journal:  Conf Proc IEEE Eng Med Biol Soc        ISSN: 1557-170X


  11 in total

1.  Computer modeling of mitochondrial tricarboxylic acid cycle, oxidative phosphorylation, metabolite transport, and electrophysiology.

Authors:  Fan Wu; Feng Yang; Kalyan C Vinnakota; Daniel A Beard
Journal:  J Biol Chem       Date:  2007-06-25       Impact factor: 5.157

2.  Experimentally observed phenomena on cardiac energetics in heart failure emerge from simulations of cardiac metabolism.

Authors:  Fan Wu; Jianyi Zhang; Daniel A Beard
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-08       Impact factor: 11.205

Review 3.  Energy metabolism in heart failure and remodelling.

Authors:  Joanne S Ingwall
Journal:  Cardiovasc Res       Date:  2008-11-05       Impact factor: 10.787

4.  Effects of augmented delivery of pyruvate on myocardial high-energy phosphate metabolism at high workstate.

Authors:  K Ochiai; J Zhang; G Gong; Y Zhang; J Liu; Y Ye; X Wu; H Liu; Y Murakami; R J Bache; K Ugurbil; A H From
Journal:  Am J Physiol Heart Circ Physiol       Date:  2001-10       Impact factor: 4.733

5.  Oxidative capacity in failing hearts.

Authors:  Guangrong Gong; Jingbo Liu; Peihua Liang; Tao Guo; Qingsong Hu; Ko Ochiai; Mingxiao Hou; Yun Ye; Xiaoyun Wu; Abdul Mansoor; Arthur H L From; Kamil Ugurbil; Robert J Bache; Jianyi Zhang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-04-24       Impact factor: 4.733

6.  31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure.

Authors:  S Neubauer; T Krahe; R Schindler; M Horn; H Hillenbrand; C Entzeroth; H Mader; E P Kromer; G A Riegger; K Lackner
Journal:  Circulation       Date:  1992-12       Impact factor: 29.690

Review 7.  Matching coronary blood flow to myocardial oxygen consumption.

Authors:  Johnathan D Tune; Mark W Gorman; Eric O Feigl
Journal:  J Appl Physiol (1985)       Date:  2004-07

8.  Phosphate metabolite concentrations and ATP hydrolysis potential in normal and ischaemic hearts.

Authors:  Fan Wu; Eric Y Zhang; Jianyi Zhang; Robert J Bache; Daniel A Beard
Journal:  J Physiol       Date:  2008-07-10       Impact factor: 5.182

9.  Depressed mitochondrial transcription factors and oxidative capacity in rat failing cardiac and skeletal muscles.

Authors:  A Garnier; D Fortin; C Deloménie; I Momken; V Veksler; R Ventura-Clapier
Journal:  J Physiol       Date:  2003-06-24       Impact factor: 5.182

10.  Supranormal myocardial creatine and phosphocreatine concentrations lead to cardiac hypertrophy and heart failure: insights from creatine transporter-overexpressing transgenic mice.

Authors:  Julie Wallis; Craig A Lygate; Alexandra Fischer; Michiel ten Hove; Jürgen E Schneider; Liam Sebag-Montefiore; Dana Dawson; Karen Hulbert; Wen Zhang; Mei Hua Zhang; Hugh Watkins; Kieran Clarke; Stefan Neubauer
Journal:  Circulation       Date:  2005-11-15       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.